Posted by Michael Wonder on 30 Jan 2024
Ascidian Therapeutics announces fast tracks ACDN-01 in Stargardt disease and other ABCA4 retinopathies
29 January 2024 - Ascidian Therapeutics today announced that the US FDA has granted fast track designation for ACDN-01.
ACDN-01 is the first ever clinical stage RNA exon editor and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease.
